Two new groundbreaking obesity studies could change the future of treatments
Novo Nordisk, a global leader in obesity medicine, has recently released exciting trial results that may shape the future of weight loss therapies. Two groundbreaking studies — the STEP UP and REDEFINE 1 trials — are shedding light on the potential for even better weight loss results with higher dosing of the medications currently in use or through new medications that may hit the market soon.
Here is what we know from the trial results and how it may impact your weight loss journey:
Understanding the STEP UP Trial
What Is the STEP UP Trial?
The STEP UP trial is a 72‑week study that explored whether increasing the dose of semaglutide from the standard 2.4 mg to 7.2 mg could help patients lose even more weight. All participants received the medication via a once‑weekly injection combined with diet and exercise advice.
Key findings:
Improved results over standard dose:
Compared to the standard 2.4 mg dose (which led to about 17.5% weight loss) and placebo (only 2.4%), the 7.2 mg dose showed an average weight loss of 20.7%.Safety and tolerability:
The higher dose was well tolerated, with most side effects being mild to moderate and mainly related to the digestive system (like nausea or mild stomach discomfort) that typically diminish over time.
For patients considering obesity treatment options, these findings suggest that a higher dose of semaglutide might help you achieve greater weight loss without compromising safety.
Spotlight on the REDEFINE 1 Trial
What Is CagriSema?
CagriSema is an innovative combination therapy that includes both semaglutide and cagrilintide. You may be wondering, ‘Well I know how semaglutide works but what in the world is cagrilintide?” Cagrilintide mimics a natural hormone in your body called amylin which helps you feel fuller, so you eat less and support your weight loss efforts.These two medications work together to help reduce hunger and promote fullness, leading to significant weight loss.
Trial overview:
The REDEFINE 1 trial lasted 68 weeks and included over 3,400 adults with obesity or overweight conditions. It compared the effects of CagriSema to its individual components and a placebo.
Key Findings:
Impressive weight loss:
Patients receiving CagriSema lost an average of 22.7% of their body weight.High achievement rates:
More than 40% of patients on CagriSema reached the landmark of losing 25% or more of their body weight—a level that many find life-changing.Safety profile:
The side effects were mostly gastrointestinal and generally mild to moderate, meaning any discomfort tends to improve with time.
Although CagriSema’s weight loss results were slightly below the company’s ambitious 25% target, the benefits remain significant. Novo Nordisk is using these insights to guide further studies, which may lead to even more effective treatments soon.
How do they compare with other injectable treatments?
Recent advances in obesity medications have raised the bar for weight loss results. For example:
Wegovy (Semaglutide 2.4 mg): Traditional trials of Wegovy typically show weight loss results ranging from about 15% when used in combination with diet and exercise.
Eli Lilly’s Zepbound (Tirzepatide): Clinical studies of Zepbound have reported weight loss figures of approximately 20% when used in combination with diet and exercise.
This enhanced efficacy, alongside a manageable side effect profile, may provide hope for those who haven’t experienced satisfactory results with existing treatments.
What does this mean for you?
Personalized obesity care:
These trials highlight the move toward more personalized medicine in obesity treatment. Whether you’re considering a higher dose of semaglutide or a combination therapy like CagriSema, discussing these options with your health care provider can help determine the best treatment plan for your unique needs.
Improved safety and efficacy:
Both studies confirm that these innovative treatments not only help you lose a significant amount of weight but also come with a safety profile that is generally well tolerated. As research continues, future treatments may become even more tailored, offering additional benefits and greater weight loss.
Looking ahead:
Novo Nordisk has further phase 3 trials on the horizon, including studies in patients with type 2 diabetes, which could lead to the development of even more effective and personalized therapies.
If you’re interested in a weight-loss program and want to schedule a free, 10-minute consultation or an appointment with our obesity medicine board-certified doctor, book one below.
